Nitazenes, also known as benzimidazole-opioids, are a group of synthetic opioids that have become increasingly relevant in recent years. First synthesized in the late 1950s by the Swiss chemical company CIBA Aktiengesellschaft, these novel non-fentanyl synthetic opioids were originally developed as potential pain medications but never approved for clinical use [1]. Today, nitazenes are being detected in the unregulated global drug supply, including Canada.